Zealand, Roche Start Petrelintide Phase 3 as 100% Pharma Tariffs Begin
Tuesday, September 29, 2026 · 9 min
Zealand Pharma and Roche have launched a roughly 7,000-person Phase 3 program for once-weekly petrelintide in obesity. Meanwhile, a baseline 100 percent Section 232 tariff on imported patented medicines and ingredients takes effect and EASD convenes in Milan.
Listen
Show notes
Zealand Pharma and Roche have launched a roughly 7,000-person Phase 3 program for once-weekly petrelintide in obesity. Meanwhile, a baseline 100 percent Section 232 tariff on imported patented medicines and ingredients takes effect and EASD convenes in Milan.
In this episode
- Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma - Medical Update Online — Medical Update Online
Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma - Medical Update Online # Global Registrational Phase 3 ZUPREME Program Evaluating Petrelintide in Overweight or Obesity Initiated – Zealand Pharma Written by Charlie King | 27 Sep 2026 | Diabetes & Endocrinology Zealand Pharma A/S announces the initiation of the global…
- Navigating Pharma’s Forced Supply Chain Revolution - Chemistry Today — Chemistry Today
Navigating Pharma’s Forced Supply Chain Revolution - Chemistry Today # Navigating Pharma’s Forced Supply Chain Revolution by info@teknoscienze.com 28 September 2026 M. Klote 28 September 2026 Molly Klote, MD President and CEO, Klote Medical Research Advisors, LLC, Washington, DC, United States Former Director, Office for Human Research Protections, US Department of Health and Human…
- EASD 2026 to Feature New Diabetes Approaches in T1DM, T2DM, obesity - Dagensdiabetes — Dagens Diabetes
EASD 2026 to Feature New Diabetes Approaches in T1DM, T2DM, obesity - Dagensdiabetes Senaste Nr DiabetologNytt i PDF ## EASD 2026 to Feature New Diabetes Approaches in T1DM, T2DM, obesity Key Points • This year’s European Association for the Study of Diabetes (EASD) 2026 Annual Meeting in Milan, Italy, (from September 28 to October 2) will feature new data on first-line treatment approaches…
- Republicans and Democrats Find a Unifying Target: Pharmacy Benefit Managers — KFF Health News
Amye Joseph says America’s political polarization has made it an “interesting time” in her Tennessee household. She and her husband, Charlie, have been married 35 years. She’s a Republican. He’s a Democrat. But their shared disenchantment with profit-driven healthcare has provided a unifying target: pharmacy benefit managers, known as PBMs. The Josephs’ frustration is focused on CVS Health. The…
- Oral solid dose at a turning point: Scaling for the next generation of therapies - Pharmaceutical Technology — Pharmaceutical Technology
Oral solid dose at a turning point: Scaling for the next generation of therapies - Pharmaceutical Technology # Oral solid dose at a turning point: Scaling for the next generation of therapies From patient-centric designs and sustainable changes to component shortages, anti-counterfeiting, and low-volume production, sponsors of oral solid dose pharmaceuticals and their CDMOs are navigating a…